reports
- Guy Sips
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
DEME signs contract to reinforce the Lekdijk in the Netherlands
DEME signs contract to reinforce the Lekdijk in the Netherlands DEME has signed a contract for reinforcement of the Lekdijk in the Netherlands. For this project, DEME is working together with Heijmans and GMB in the Lekensemble consortium to reinforce the dike between Wijk bij Duurstede and Amerongen (WAM). Commissioned by Hoogheemraadschap De Stichtse Rijnlanden, this vital project is part of the Dutch Flood Protection Program and aims to safeguard hundreds of thousands of residents from high water. Attachment
DEME tekent contract voor versterking van de Lekdijk in Nederland
DEME tekent contract voor versterking van de Lekdijk in Nederland DEME heeft een contract getekend voor de versterking van de Lekdijk in Nederland. Voor dit project werkt DEME samen met Heijmans en GMB binnen het consortium Lekensemble om de dijk tussen Wijk bij Duurstede en Amerongen (WAM) te versterken. In opdracht van Hoogheemraadschap De Stichtse Rijnlanden maakt dit essentiële project deel uit van het Hoogwaterbeschermingsprogramma, met als doel honderdduizenden inwoners te beschermen tegen hoogwater. Bijlage
DEME launches liquidity program
DEME launches liquidity program DEME Group NV today announced the launch of a liquidity program designed to enhance the trading liquidity of its shares, reduce volatility, and improve overall market access and flexibility. The program will be managed by KBC Securities, acting as independent intermediary, and will be conducted in compliance with all applicable rules and regulations. The liquidity program will commence on September 15, 2025. “We are pleased to launch this program, which reflects our commitment to ensuring efficient trading conditions and supporting our shareholder base,” sa...
DEME lanceert liquiditeitsprogramma
DEME lanceert liquiditeitsprogramma DEME Group NV maakt vandaag bekend dat het een liquiditeitsprogramma lanceert om de verhandelbaarheid van zijn aandelen te verbeteren, en zo de volatiliteit te verminderen en de drempel naar een meer toegankelijke markt te verlagen. Het programma zal worden beheerd door KBC Securities, die optreedt als onafhankelijke tussenpersoon, en zal worden uitgevoerd in overeenstemming met alle toepasselijke regels en voorschriften. Het liquiditeitsprogramma gaat van start op 15 september 2025. “We zijn verheugd dit programma te lanceren met het oog op een meer ef...
- ING Helpdesk
Benelux Morning Notes
Ageas: Highlights ING Benelux Conference London. Alfen: Highlights from ING Benelux Conference London. Arcadis: Highlights ING Benelux Conference London. ASR: Highlights ING Benelux Conference London. BAM: Highlights ING Benelux Conference London. Basic-Fit: Highlights ING Benelux Conference London. CTP: Highlights from ING Benelux Conference London. DEME Group: Highlights ING Benelux Conference London. Fugro: Highlights ING Benelux Conference London. Heijmans: Highlights ING Bene...
SBMO SBM OFFSHORE NV
AGS AGEAS SA/NV
RAND RANDSTAD NV
PNL POSTNL NV
BAMNB KONINKLIJKE BAM GROEP NV
LOTB LOTUS BAKERIES NV
HEIJM HEIJMANS N.V. CERT
ARCAD
ARCADIS NV
ASRNL ROYAL VOPAK NV
TWEKA ASR NEDERLAND NV
ALFEN TKH GROUP N.V. CERT
FUR ALFEN NV
CTPNV FUGRO NV
DEME CTP NV
DEME GROUP NV
Inventiva to Participate in Upcoming September Investor Conferences
Inventiva to Participate in Upcoming September Investor Conferences Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fi...
Inventiva annonce sa participation à plusieurs conférences investisseu...
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son équipe de direction participera aux conférences investisseurs suivantes :H.C. Wainwright 27th Annual Global Investment Conference Date : Mardi 9 septembre 2025Heur...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update September: Adding AB InBev and Exor
In this September update we added 2 stocks to the KBC Securities Dynamic Top Pick List : We added AB InBev after the share price weakened post-2Q results. ABI's 2Q volumes fell 1.9% organically, below expectations, mainly due to a 9% drop in Brazil where a price hike led to temporary market share loss. However, strong revenue per hl growth (+4.9%) drove a 6.5% organic EBITDA increase, with 1H growth at +7.2%, near the top of FY guidance (+4–8%). AB InBev, the world's largest brewer, generates ...
Share buyback program completed
Share buyback program completed DEME Group NV announces that the share buyback program, which commenced on April 22, 2025, was completed on September 1, 2025. The program involved the buyback of 40,000 shares for a total amount of 5,345,737 million euros. The average purchase price was 133.64 euros per share.All details related to the acquisition of own shares by DEME Group NV can be found on . Attachment
Programma inkoop eigen aandelen voltooid
Programma inkoop eigen aandelen voltooid DEME Group NV kondigt aan dat het aandeleninkoopprogramma, zoals aangekondigd op 22 april 2025, werd afgerond op 1 september 2025. Het programma omvatte de inkoop van 40.000 aandelen voor een totaalbedrag van 5.345.737 miljoen euro. De gemiddelde aankoopprijs was 133,64 euro per aandeel. Alle details over de inkoop van eigen aandelen door DEME Group NV zijn beschikbaar op . Bijlage
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Inventiva A MASH turnaround story with big upside potential
Inventiva's lanifibranor is the next in line candidate in MASH, with its phase 3 (NATiV3) trial now fully recruited, locking in a topline readout for 2H26. The program is de-risked by a robust phase 2b, showing competitive fibrosis response rates and strong HbA1c reduction— a key differentiator for the large MASH + T2D population. With oral dosing and clean safety, lanifibranor is well-positioned to capture a meaningful share of the validated MASH commercial opportunity. A € 348m structured fina...
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, s...
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Regulated information August 27, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Group performance: Strong HealthCare IT performance and stable Digital Print & Chemicals performance not sufficiently offsetting the continued fast decline in medical filmAdjusted EBITDA decreased...
De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestati...
De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Gereglementeerde informatie 27 augustus 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Groepsprestatie: Sterke prestatie van HealthCare IT en stabiele prestatie van Digital Print & Chemicals volstaan niet om de ...
- Thijs Berkelder
- ING Helpdesk
- Guy Sips
- Kristof Samoy
- Wim Lewi
- Guy Sips
DEME Good set of 1H25 results but impacted by some non-recurring eleme...
We maintain our positive stance (Buy € 175 TP) as after a good set of 1H25 results, DEME indicated that its operations remain robust and they still expect full-year turnover to be at least in line with FY24 and now anticipate FY25 EBITDA margin to slightly exceed 20% (was before at least in line with FY24). FY25 CapEx remains forecasted at +/- €300m, excluding the expenditures for the Havfram acquisition and the completion and delivery of its two vessels, which will significantly boost DEME's su...
Half-year results 2025: strong first half delivers record profitabilit...
Half-year results 2025: strong first half delivers record profitability; full-year EBITDA guidance raised Highlights Group turnover grew 10% year-over-year to 2.1 billion euros, driven by continued strong growth in Offshore EnergyEBITDA increased 35% to a record level of 464 million euros, or 21.9% of turnover, up from 345 million euros, or 18.0% of turnover, for the first half of 2024Net profit increased 27%, reaching 179 million euros, compared to 141 million euros a year agoDEME acquired Havfram, a Norwegian offshore wind contractor, reinforcing its ambition to expand in the offshore w...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.